Professor John Strang

John Strang is the Director of the National Addiction Centre (Institute of Psychiatry, King’s College London) where he leads the multidisciplinary research activities including treatment studies, investigations of non-treatment samples, studies of overdose risk and analyses of public policy, as well as giving leadership to the development and provision of treatments across the addictions field. He also leads the Addictions Clinical Academic Group (CAG) of King’s Health Partners, a new Academic Health Sciences Centre (AHSC) comprising the university King’s College London (KCL) as well as the SLaM NHS Foundation Trust.

He has worked in the addictions field more than 30 years, in statutory and non-statutory settings, as trainee and trainer, as clinician as well as researcher, and in policy formation as well as practitioner capacity.

John Strang has worked with various organisations and advisory bodies, including the Society for the Study of Addiction (SSA) and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). He has also worked closely with the charity Action on Addiction, and also with the J Paul Getty Charitable Trust (JPGT) and the Pilgrim Trust, and has received grant support from them. He has also had previous close links with charitable funded providers, including Lifeline (Manchester), Phoenix House, and currently with KCAUK(Kent Council on Addictions), and Clouds (Action on Addiction).

He has received project grant support and/or honoraria and/or consultancy payments from organisations including Department of Health, NTA (National Treatment Agency), Home Office, NICE (National Institute for Health and Clinical Excellence) and EMCDDA (European Monitoring Centre for Drugs and Drug Addiction). He has worked with WHO (World Health Organisation) and with UNODC (United Nations Office for Drug Control) and other international government agencies. He has also received research grant support and/or honoraria, consultancy payments and/or expenses from several pharmaceutical companies who produce, or have been considering producing, new medicines for use in the addiction treatment field.

Search our Findings documents